Target Name: EVA1C
NCBI ID: G59271
Other Name(s): B19 | B18 | EVA-1 | C21orf64 | Protein FAM176C | EVA1C variant 2 | Protein eva-1 homolog C (isoform 2) | EVA1 | Eva-1 homolog | FAM176C | Eva-1 homolog C, transcript variant 1 | eva-1 homolog C | protein FAM176C | Eva-1 homolog C, transcript variant 2 | EVA1C_HUMAN | EVA1C variant 1 | Protein eva-1 homolog C (isoform 1) | C21orf63 | Family with sequence similarity 176, member C | PRED34 | SUE21 | Protein eva-1 homolog C | family with sequence similarity 176, member C

EVA1C: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

EVA1C (B19) is a protein that is expressed in various tissues of the body, including the brain, heart, and liver. It is a member of the beta-sheet family of transmembrane proteins, which are characterized by the presence of a protein domain that is responsible for the protein's transmembrane properties and the ability to interact with various intracellular signaling molecules.

Recent studies have identified EVA1C as a potential drug target (or biomarker) due to its involvement in several cellular processes that are associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will explore the biology and function of EVA1C, as well as its potential as a drug target.

Structure and Expression

The beta-sheet family of proteins is characterized by the presence of a protein domain that is responsible for the protein's transmembrane properties and the ability to interact with various intracellular signaling molecules. The protein domain is typically composed of a series of parallel beta-strands that are arranged in a specific pattern, such as a 尾-hierarchy. This arrangement allows the protein domain to fold into a specific 3D structure that is responsible for the protein's transmembrane properties and its ability to interact with signaling molecules.

EVA1C is a member of the beta-sheet family of transmembrane proteins and is expressed in various tissues of the body, including the brain, heart, and liver. It is characterized by the presence of a protein domain that is responsible for its transmembrane properties and its ability to interact with various intracellular signaling molecules.

Function

EVA1C is involved in several cellular processes that are associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In cancer, EVA1C has been shown to be involved in the regulation of cell cycle progression, apoptosis, and angiogenesis. For example, EVA1C has been shown to play a role in the regulation of the G1/S transition, which is a critical step in the cell cycle that is associated with the growth and development of cancer.

In neurodegenerative diseases, EVA1C has been shown to be involved in the regulation of neurotransmitter synthesis and release, as well as the regulation of cellular signaling pathways that are involved in neurodegeneration. For example, EVA1C has been shown to play a role in the regulation of the production of neurotransmitters, such as dopamine and serotonin, which are involved in the regulation of mood, emotion, and pain.

In autoimmune disorders, EVA1C has been shown to be involved in the regulation of immune cell function and the regulation of inflammation. For example, EVA1C has been shown to play a role in the regulation of the production of antibodies, which are involved in the immune response.

Drug Targeting

EVA1C is a potential drug target (or biomarker) due to its involvement in several cellular processes that are associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One potential approach to targeting EVA1C is to use small molecules that can modulate its expression or activity. For example, drugs that can inhibit the activity of EVA1C signaling molecules, such as the protein kinase B, have been shown to be effective in treating neurodegenerative diseases.

Another potential approach to targeting EVA1C is to use antibodies that can specifically recognize and target EVA1C. For example, antibodies that recognize EVA1C have been shown to be effective in treating

Protein Name: Eva-1 Homolog C

Functions: Binds heparin

More Common Targets

EVC | EVC2 | EVI2A | EVI2B | EVI5 | EVI5L | EVL | EVPL | EVPLL | EVX1 | EVX1-AS | EVX2 | EWSAT1 | EWSR1 | EXD1 | EXD2 | EXD3 | EXO1 | EXO5 | EXOC1 | EXOC1L | EXOC2 | EXOC3 | EXOC3-AS1 | EXOC3L1 | EXOC3L2 | EXOC3L4 | EXOC4 | EXOC5 | EXOC5P1 | EXOC6 | EXOC6B | EXOC7 | EXOC8 | Exocyst complex | EXOG | EXOGP1 | Exon junction complex | EXOSC1 | EXOSC10 | EXOSC10-AS1 | EXOSC2 | EXOSC3 | EXOSC4 | EXOSC5 | EXOSC6 | EXOSC7 | EXOSC8 | EXOSC9 | Exosome Complex | EXPH5 | EXT1 | EXT2 | EXTL1 | EXTL2 | EXTL2P1 | EXTL3 | EXTL3-AS1 | EYA1 | EYA2 | EYA3 | EYA4 | EYS | EZH1 | EZH2 | EZHIP | EZR | F10 | F11 | F11-AS1 | F11R | F12 | F13A1 | F13B | F2 | F2R | F2RL1 | F2RL2 | F2RL3 | F3 | F5 | F7 | F8 | F8A1 | F8A2 | F8A3 | F9 | FA2H | FAAH | FAAH2 | FAAHP1 | FAAP100 | FAAP20 | FAAP24 | FABP1 | FABP12 | FABP2 | FABP3 | FABP4 | FABP5